Fulgent Genetics, Inc. (FLGT)
NASDAQ: FLGT · Real-Time Price · USD
18.52
+1.34 (7.80%)
At close: Aug 1, 2025, 4:00 PM
18.53
+0.01 (0.05%)
After-hours: Aug 1, 2025, 7:28 PM EDT
Revance Therapeutics Revenue
Fulgent Genetics had revenue of $81.80M in the quarter ending June 30, 2025, with 15.17% growth. This brings the company's revenue in the last twelve months to $303.22M, up 4.31% year-over-year. In the year 2024, Fulgent Genetics had annual revenue of $283.47M, down -1.99%.
Revenue (ttm)
$303.22M
Revenue Growth
+4.31%
P/S Ratio
1.87
Revenue / Employee
$230,939
Employees
1,313
Market Cap
564.12M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 283.47M | -5.74M | -1.99% |
| Dec 31, 2023 | 289.21M | -329.76M | -53.27% |
| Dec 31, 2022 | 618.97M | -373.62M | -37.64% |
| Dec 31, 2021 | 992.58M | 570.87M | 135.37% |
| Dec 31, 2020 | 421.71M | 389.18M | 1,196.46% |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 90.63B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 49.00B |
| Novo Nordisk | 43.92B |
FLGT News
- 14 hours ago - Fulgent Genetics, Inc. (FLGT) Q2 2025 Earnings Call Transcript - Seeking Alpha
- 20 hours ago - Fulgent Reports Second Quarter 2025 Financial Results - Business Wire
- 15 days ago - Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM - Business Wire
- 22 days ago - Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025 - Business Wire
- 7 weeks ago - Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Fulgent Genetics, Inc. (FLGT) And Encourages Shareholders to Reach Out - Accesswire
- 7 weeks ago - Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulgent Genetics, Inc. (FLGT) and Encourages Shareholders to Learn More About the Investigation - Accesswire
- 7 weeks ago - Fulgent Genetics, Inc. (FLGT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - Accesswire
- 2 months ago - Bronstein, Gewirtz & Grossman, LLC Encourages Fulgent Genetics, Inc. (FLGT) Shareholders to Inquire about Securities Investigation - Accesswire